Richard H. Stanford
Research Triangle Park
146 Papers
838 Citations
Richard H. Stanford is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Fluticasone propionate & Asthma. The author has an hindex of 31, co-authored 141 publications. Previous affiliations of Richard H. Stanford include GlaxoSmithKline.
Chat about Author
Papers
Cost-Efficacy Analysis of Fluticasone Propionate versus Zafirlukast in Patients with Persistent Asthma
TL;DR: Treatment with fluticasone propionate 88μg twice daily was the most cost effective treatment compared with zafirlukast 20mg twice daily in this 12-week clinical trial, and this analysis supports the use of flutica propionates twice daily as first-line treatment in patients with persistent asthma previously treated with short-acting β2-agonist alone.
19
•Journal Article
Asthma: resource use and costs for inhaled corticosteroid vs leukotriene modifier treatment--a meta-analysis.
TL;DR: Patients with asthma treated with inhaled corticosteroids have significantly fewer asthma-related hospitalizations and emergency department visits and lower total asthma- related health care costs than patients treated with leukotriene modifiers.
18
An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes
TL;DR: In this observational study using a large managed-care database, subjects treated with FSC were at significantly less risk for developing serious asthma exacerbations and had lower resource utilization than a cohort of subjects treating with FP.
17
Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
TL;DR: Almost 25% of patients with COPD progressed to triple therapy within 12 months of initiating treatment with monotherapy or dual therapy, and treatment discontinuation, smoking history, the use of a LAMA, and concomitant medication use were significant predictors of progression to triple Therapy.
Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall.
TL;DR: Summertime dispensings of FSC were associated with a decreased risk of serious asthma-related outcomes in the subsequent fall, and this protective effect persisted even for patients with fall dispensed FSC.
16